Zentalis Pharmaceuticals announced its 2025 financial results and progress on its ovarian cancer drug azenosertib, highlighting completed enrollment in the DENALI Part 2a trial and plans to start the Phase 3 ASPENOVA trial in early 2026. The DENALI trial's topline results are expected by the end of 2026 and could support accelerated FDA approval. The company has $245.9 million in cash, funding operations into late 2027, and is expanding azenosertib's potential in ovarian cancer treatment, including combination therapies. These developments position 2026 as a pivotal year for Zentalis' clinical and regulatory milestones.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
California American Water and Sonoma County Fire District completed projects reducing wildfire risk around water facilities in Sonoma County. The efforts included clearing flammable vegetation near critical infrastructure like water storage tanks and...
